antiviral news

Press Releases in the global landscape

Feb 19, 2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options.

Feb 5, 2026

The Ministry of Health has approved nine home treatment regimens for COVID-19

Feb 1, 2026

The Ministry of Health approved permanent recommendations for the treatment of COVID-19

Among the drugs recommended for use in outpatient settings are molnupiravir, favipiravir, nirmatrelvir with ritonavir, as well as other active substances.

Jan 27, 2026

Chinese scientists identify oral drug VV116 as promising Nipah virus treatment

A new study by several Chinese research teams has found that the oral nucleoside drug VV116 possesses strong antiviral activity against the Nipah virus (NiV), offering fresh hope in the fight against this emerging highly lethal infectious disease, according to the Wuhan Institute of Virology, Chinese Academy of Sciences.

Jan 26, 2026

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options.

Jan 22, 2026

Ensitrelvir Shows Promise as Effective COVID-19 Antiviral in Phase 2 Trial

A new study published in the journal of The Lancet Infectious Diseases showed that an efficient substitute for current COVID-19 therapies is ensitrelvir, a once-daily oral SARS-CoV-2 protease inhibitor developed by Shionogi. The current oral first-line medication for COVID-19, ritonavir-boosted nirmatrelvir, shares a molecular target (the primary protease) with ensitrelvir.